Author

Marta Sorokina Alexdóttir

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marta Sorokina Alexdóttir  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

Marta Sorokina Alexdóttir  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN'S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN'S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

Marta Sorokina Alexdóttir  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Marta Sorokina Alexdóttir  et al.

Item 1 - 6 / 6
1